Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/4/2025 | $19.00 | Buy | Canaccord Genuity |
| 7/28/2025 | $24.00 | Outperform | Oppenheimer |
| 7/16/2025 | $16.00 | Buy | Citigroup |
| 6/11/2025 | $14.00 | Outperform | Raymond James |
| 4/29/2025 | $10.00 | Overweight | Cantor Fitzgerald |
| 4/8/2025 | $18.00 | Outperform | Wedbush |
| 2/25/2025 | $26.00 | Buy | Jefferies |
| 10/16/2024 | $22.00 | Outperform → Strong Buy | Raymond James |
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg multidose cohort has potential to deliver further increases in serum AAT Data from 200 mg and 400 mg cohorts support monthly or less frequent subcutaneous dosing; 400 mg monthly multidose cohort data expected in 1Q 2026 WVE-0
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 WVE-007, an INHBE GalNAc-siRNA designed to induce fat loss with muscle preservation, dosing is complete in expanded Cohort 2 (240 mg; from 8 to 32 individuals) of INLIGHT trial at dose predict
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
144 - Wave Life Sciences Ltd. (0001631574) (Subject)
144 - Wave Life Sciences Ltd. (0001631574) (Subject)
Canaccord Genuity initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $19.00
Oppenheimer initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $24.00
Citigroup initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $16.00
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg multidose cohort has potential to deliver further increases in serum AAT Data from 200 mg and 400 mg cohorts support monthly or less frequent subcutaneous dosing; 400 mg monthly multidose cohort data expected in 1Q 2026 WVE-0
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 WVE-007, an INHBE GalNAc-siRNA designed to induce fat loss with muscle preservation, dosing is complete in expanded Cohort 2 (240 mg; from 8 to 32 individuals) of INLIGHT trial at dose predict
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company's second quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)